Pfizer stock sees mild rebound above $25.98 but upside momentum capped near resistance

Traders Union
All News
Companies
Pfizer gains 1.17% today at $25.98

Highlights

Pfizer shares show short-term stabilization above support, but remain under medium and long-term technical resistance.
Momentum and trend indicators signal ongoing weakness, with low probability of an upside breakout and seller dominance persisting.
Expected range next week is $25.27–$25.51, with downside risk if support fails and limited potential for upward moves above $26.05.

Short-term stabilization as resistance caps rebound potential

Pfizer’s share price ($25.98) sits just above the MA-20 ($25.80) but remains under the MA-50 ($26.62) and MA-200 ($25.84) on the daily chart, indicating short-term stabilization but continued medium and long-term pressure from sellers. The Ichimoku Kijun at $26.05 is above the current price, acting as immediate resistance. Near-term support is defined by the MA-20 ($25.80), with key support at the MA-200 ($25.84). Immediate resistance is the Ichimoku Kijun ($26.05), followed by key resistance at the MA-50 ($26.62).

Mixed momentum and weak trend as rebound stalls near resistance

Momentum remains weak as MACD on D1 shows a strong sell bias and ADX on D1 signals a lack of trend strength. RSI on D1 is bearish at 43.94, while Stoch RSI signals improving conditions but is not at extreme levels. CCI is neutral. BBP is positive and forecasts a buy, reflecting intraday buyer dominance despite the mixed picture from other oscillators. In today’s session, Pfizer is up 1.17%, signaling a rebound attempt. Over the past week, Pfizer has declined $0.23 (0.86%) from a previous weekly close of $26.21, with the price now at the very top of the weekly range. Weekly volatility stands at 2.53%. The tone shows a minor recovery from the recent low, but overall price action has been consolidative near resistance.

Bearish risk dominates as key resistance limits breakout odds

For the coming week, the expected trading range is $25.27–$25.51, keeping the action just above the recent 52-week low of $23.11 but below the $28.74 high. The probability of a price increase is very low (less than 20%), while the likelihood of a decline is much higher given the weak MACD and RSI signals on W1 and persistent selling pressure in major averages. The baseline scenario is for Pfizer to remain rangebound, with resistance near $26.05 keeping upward moves in check. A bullish outcome would require a decisive break above $26.05, opening a test of the MA-50 and further resistance near $26.62. On the downside, a break below $25.80–$25.84 support could accelerate declines toward the weekly forecast low of $25.27. Overall, sideways to slightly bearish risk dominates with limited prospects for a breakout upward in the near term.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Pfizer shares faced sustained bearish momentum, with analysts cautioning that further downside was more likely unless a technical breakout occurred. As the current article discusses renewed market interest and potential catalysts, investors should monitor for any shift in sentiment that could signal a change in Pfizer's prevailing downtrend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.